Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 540 participants.

Also called NCT01313533

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 1/2
Enrolled
  • 540 participants (planned count) (from the registry)
Sponsor
St. Luke's Hospital, Chesterfield, Missouri (from the registry)
Registry
  • NCT NCT01313533
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01313533. Randomized; quadruple masking; primary purpose prevention. Start 2015-03 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
Condition
Atherosclerosis
Intervention (Drug)
Polyarginine
Intervention (Drug)
Vein soak treated with Lactated Ringers Solution
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri (class: other)

Record details

Record id
cardio:ct-nct01313533
Content hash
3aab8feee1fd686494262f01f5045bc832072b4d33164289a21be46211faf121